Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Fluoxetine attenuates the impairment of spatial learning ability and prevents neuron loss in middle-aged APPswe/PSEN1dE9 double transgenic Alzheimer's disease mice.

Ma J, Gao Y, Jiang L, Chao FL, Huang W, Zhou CN, Tang W, Zhang L, Huang CX, Zhang Y, Luo YM, Xiao Q, Yu HR, Jiang R, Tang Y.

Oncotarget. 2017 Apr 25;8(17):27676-27692. doi: 10.18632/oncotarget.15398.

2.

Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification.

Lauterbach EC.

Neural Regen Res. 2016 Nov;11(11):1712-1726. doi: 10.4103/1673-5374.194708. Review.

3.

Effects of Anthocyanins on CAG Repeat Instability and Behaviour in Huntington's Disease R6/1 Mice.

Møllersen L, Moldestad O, Rowe AD, Bjølgerud A, Holm I, Tveterås L, Klungland A, Retterstøl L.

PLoS Curr. 2016 Jul 5;8. pii: ecurrents.hd.58d04209ab6d5de0844db7ef5628ff67. doi: 10.1371/currents.hd.58d04209ab6d5de0844db7ef5628ff67.

4.

Genetic deletion of the Histone Deacetylase 6 exacerbates selected behavioral deficits in the R6/1 mouse model for Huntington's disease.

Ragot A, Pietropaolo S, Vincent J, Delage P, Zhang H, Allinquant B, Leinekugel X, Fischer A, Cho YH.

Brain Behav. 2015 Sep;5(9):e00361. doi: 10.1002/brb3.361. Epub 2015 Jun 24.

5.

Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?

Du X, Pang TY.

Front Psychiatry. 2015 Mar 9;6:32. doi: 10.3389/fpsyt.2015.00032. eCollection 2015. Review.

6.

HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity.

Mattis VB, Tom C, Akimov S, Saeedian J, Østergaard ME, Southwell AL, Doty CN, Ornelas L, Sahabian A, Lenaeus L, Mandefro B, Sareen D, Arjomand J, Hayden MR, Ross CA, Svendsen CN.

Hum Mol Genet. 2015 Jun 1;24(11):3257-71. doi: 10.1093/hmg/ddv080. Epub 2015 Mar 3.

7.

Amitriptyline improves motor function via enhanced neurotrophin signaling and mitochondrial functions in the murine N171-82Q Huntington disease model.

Cong WN, Chadwick W, Wang R, Daimon CM, Cai H, Amma J, Wood WH 3rd, Becker KG, Martin B, Maudsley S.

J Biol Chem. 2015 Jan 30;290(5):2728-43. doi: 10.1074/jbc.M114.588608. Epub 2014 Dec 11.

8.

Physical exercise-induced adult neurogenesis: a good strategy to prevent cognitive decline in neurodegenerative diseases?

Yau SY, Gil-Mohapel J, Christie BR, So KF.

Biomed Res Int. 2014;2014:403120. doi: 10.1155/2014/403120. Epub 2014 Apr 9. Review.

9.

Mood disorders in Huntington's disease: from behavior to cellular and molecular mechanisms.

Pla P, Orvoen S, Saudou F, David DJ, Humbert S.

Front Behav Neurosci. 2014 Apr 23;8:135. doi: 10.3389/fnbeh.2014.00135. eCollection 2014. Review.

10.

Results of the citalopram to enhance cognition in Huntington disease trial.

Beglinger LJ, Adams WH, Langbehn D, Fiedorowicz JG, Jorge R, Biglan K, Caviness J, Olson B, Robinson RG, Kieburtz K, Paulsen JS.

Mov Disord. 2014 Mar;29(3):401-5. doi: 10.1002/mds.25750. Epub 2013 Dec 27.

11.

Neuroprotective effects of psychotropic drugs in Huntington's disease.

Lauterbach EC.

Int J Mol Sci. 2013 Nov 15;14(11):22558-603. doi: 10.3390/ijms141122558. Review.

12.

High-Throughput Automated Phenotyping of Two Genetic Mouse Models of Huntington's Disease.

Balci F, Oakeshott S, Shamy JL, El-Khodor BF, Filippov I, Mushlin R, Port R, Connor D, Paintdakhi A, Menalled L, Ramboz S, Howland D, Kwak S, Brunner D.

PLoS Curr. 2013 Jul 11;5. pii: ecurrents.hd.124aa0d16753f88215776fba102ceb29. doi: 10.1371/currents.hd.124aa0d16753f88215776fba102ceb29.

13.

A Tale of Two Maladies? Pathogenesis of Depression with and without the Huntington's Disease Gene Mutation.

Du X, Pang TY, Hannan AJ.

Front Neurol. 2013 Jul 9;4:81. doi: 10.3389/fneur.2013.00081. eCollection 2013.

14.

Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.

Jiang M, Peng Q, Liu X, Jin J, Hou Z, Zhang J, Mori S, Ross CA, Ye K, Duan W.

Hum Mol Genet. 2013 Jun 15;22(12):2462-70. doi: 10.1093/hmg/ddt098. Epub 2013 Feb 27.

15.

Extensive changes in DNA methylation are associated with expression of mutant huntingtin.

Ng CW, Yildirim F, Yap YS, Dalin S, Matthews BJ, Velez PJ, Labadorf A, Housman DE, Fraenkel E.

Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2354-9. doi: 10.1073/pnas.1221292110. Epub 2013 Jan 22.

16.

Expression of mutant huntingtin in leptin receptor-expressing neurons does not control the metabolic and psychiatric phenotype of the BACHD mouse.

Lundh SH, Soylu R, Petersén A.

PLoS One. 2012;7(12):e51168. doi: 10.1371/journal.pone.0051168. Epub 2012 Dec 10.

17.

Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.

Switonski PM, Szlachcic WJ, Gabka A, Krzyzosiak WJ, Figiel M.

Mol Neurobiol. 2012 Oct;46(2):430-66. doi: 10.1007/s12035-012-8316-3. Epub 2012 Sep 4. Review.

18.

Hippocampal neurogenesis, cognitive deficits and affective disorder in Huntington's disease.

Ransome MI, Renoir T, Hannan AJ.

Neural Plast. 2012;2012:874387. doi: 10.1155/2012/874387. Epub 2012 Jun 27. Review.

19.

Patterns of serotonergic antidepressant usage in prodromal Huntington disease.

Rowe KC, Paulsen JS, Langbehn DR, Wang C, Mills J, Beglinger LJ, Smith MM, Epping EA, Fiedorowicz JG, Duff K, Ruggle A, Moser DJ; PREDICT-HD Investigators of the Huntington Study Group.

Psychiatry Res. 2012 Apr 30;196(2-3):309-14. doi: 10.1016/j.psychres.2011.09.005. Epub 2012 Mar 5.

20.

Fluoxetine rescues impaired hippocampal neurogenesis in a transgenic A53T synuclein mouse model.

Kohl Z, Winner B, Ubhi K, Rockenstein E, Mante M, Münch M, Barlow C, Carter T, Masliah E, Winkler J.

Eur J Neurosci. 2012 Jan;35(1):10-9. doi: 10.1111/j.1460-9568.2011.07933.x.

Supplemental Content

Support Center